Subscribe
Today
Financial
Technology
Cyclical
Defensive
Healthcare
Energy
Industrials
Real Estate
Materials
Viewpoints
All Access Articles |
NTLA
Intellia Therapeutics – Positive Phase 1 Data for Nexiguran Ziclumeran in ATTR-CM
| 2024-11-18 |
BIOTECHNOLOGY
Intellia Therapeutics Rallies in Gene Editing Advancements
| 2024-02-22 |
BIOTECHNOLOGY
